| scholarly article | Q13442814 |
| P356 | DOI | 10.1021/BC0502917 |
| P698 | PubMed publication ID | 16417259 |
| P2093 | author name string | Stephen C Alley | |
| Brian E Toki | |||
| Peter D Senter | |||
| Brian A Mendelsohn | |||
| Ezogelin Oflazoglu | |||
| Alan F Wahl | |||
| Charles G Cerveny | |||
| Damon L Meyer | |||
| Svetlana O Doronina | |||
| Tim D Bovee | |||
| Russell J Sanderson | |||
| Roger F Zabinski | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 114-124 | |
| P577 | publication date | 2006-01-01 | |
| P1433 | published in | Bioconjugate Chemistry | Q2343023 |
| P1476 | title | Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity | |
| P478 | volume | 17 |
| Q45870245 | A Fusion Receptor as a Safety Switch, Detection, and Purification Biomarker for Adoptive Transferred T Cells |
| Q92325617 | A coiled-coil masking domain for selective activation of therapeutic antibodies |
| Q47722278 | A non-internalizing antibody-drug conjugate based on an anthracycline payload displays potent therapeutic activity in vivo. |
| Q35764587 | A novel antibody-drug conjugate targeting SAIL for the treatment of hematologic malignancies |
| Q38845355 | A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity |
| Q57441320 | A versatile acid-labile linker for antibody–drug conjugates |
| Q99636454 | ALPPL2 is a highly specific and targetable tumor cell surface antigen |
| Q33873317 | Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells |
| Q39382257 | Advances in antibody-drug conjugates: A new era of targeted cancer therapy. |
| Q37697843 | Advances in the treatment of hematologic malignancies using immunoconjugates |
| Q38990390 | An intracellularly activatable, fluorogenic probe for cancer imaging |
| Q28538698 | An optimized triple modality reporter for quantitative in vivo tumor imaging and therapy evaluation |
| Q37858385 | Analytical methods for physicochemical characterization of antibody drug conjugates |
| Q42993852 | Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma |
| Q47750583 | Anti-glypican-1 antibody-drug conjugate exhibits potent preclinical antitumor activity against glypican-1 positive uterine cervical cancer |
| Q90171453 | Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer |
| Q38453769 | Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection |
| Q91808144 | Antibody Structure and Function: The Basis for Engineering Therapeutics |
| Q47143718 | Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? |
| Q28544658 | Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry |
| Q28270261 | Antibody drug-conjugates targeting the tumor vasculature: Current and future developments |
| Q46674963 | Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs |
| Q53739135 | Antibody-Drug Conjugates for Cancer Therapy. |
| Q52593621 | Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications. |
| Q37452241 | Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells |
| Q38014923 | Antibody-drug conjugates - a perfect synergy |
| Q38087390 | Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia |
| Q38334139 | Antibody-drug conjugates: a mini-review. The synopsis of two approved medicines. |
| Q55030497 | Anticancer nanoparticulate polymer-drug conjugate. |
| Q64119727 | Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C-Lock linker |
| Q43751494 | Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics |
| Q27667652 | Bispecific digoxigenin-binding antibodies for targeted payload delivery |
| Q39922525 | CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers |
| Q52401505 | Challenges and new frontiers in analytical characterization of antibody-drug conjugates. |
| Q37854644 | Challenges in developing bioanalytical assays for characterization of antibody-drug conjugates |
| Q45223731 | Characterization of the drug-to-antibody ratio distribution for antibody-drug conjugates in plasma/serum. |
| Q42957188 | Charge-based analysis of antibodies with engineered cysteines: from multiple peaks to a single main peak |
| Q50977893 | Conjugates of Small Molecule Drugs with Antibodies and Other Proteins. |
| Q92585782 | Considerations for the Design of Antibody-Based Therapeutics |
| Q38373185 | Current ADC Linker Chemistry |
| Q42314398 | Decoupling stability and release in disulfide bonds with antibody-small molecule conjugates. |
| Q37175328 | Design and characteristics of cytotoxic fibroblast growth factor 1 conjugate for fibroblast growth factor receptor-targeted cancer therapy |
| Q38017203 | Designing immunoconjugates for cancer therapy |
| Q46060791 | Direct Intracellular Delivery of Cell-Impermeable Probes of Protein Glycosylation by Using Nanostraws |
| Q38084826 | Drug conjugates such as Antibody Drug Conjugates (ADCs), immunotoxins and immunoliposomes challenge daily clinical practice. |
| Q37222147 | Effective antitumor therapy based on a novel antibody-drug conjugate targeting the Tn carbohydrate antigen |
| Q57911948 | Emerging classes of armed antibody therapeutics against cancer |
| Q27701980 | Enzymatic prenylation and oxime ligation for the synthesis of stable and homogeneous protein-drug conjugates for targeted therapy |
| Q37329160 | EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma |
| Q37638935 | EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma |
| Q38073792 | Epithelial cell adhesion molecule-targeted drug delivery for cancer therapy. |
| Q93098762 | Ethynylphosphonamidates for the Rapid and Cysteine-Selective Generation of Efficacious Antibody-Drug Conjugates |
| Q38764001 | Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma |
| Q38920359 | Evolving Strategies for Target Selection for Antibody-Drug Conjugates |
| Q39157615 | Expanded Utility of the β-Glucuronide Linker: ADCs That Deliver Phenolic Cytotoxic Agents |
| Q37118460 | Exploration of fluorine chemistry at the multidisciplinary interface of chemistry and biology. |
| Q26822421 | Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics |
| Q37066113 | Field Guide to Challenges and Opportunities in Antibody-Drug Conjugates for Chemists. |
| Q33438286 | First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors |
| Q55385806 | Glutamic acid-valine-citrulline linkers ensure stability and efficacy of antibody-drug conjugates in mice. |
| Q42646020 | Harnessing a catalytic lysine residue for the one-step preparation of homogeneous antibody-drug conjugates |
| Q34718363 | Harnessing the fcμ receptor for potent and selective cytotoxic therapy of chronic lymphocytic leukemia. |
| Q90333773 | High-Throughput, Multispecies, Parallelized Plasma Stability Assay for the Determination and Characterization of Antibody-Drug Conjugate Aggregation and Drug Release |
| Q90212215 | Hydrophilic Auristatin Glycoside Payload Enables Improved Antibody-Drug Conjugate Efficacy and Biocompatibility |
| Q92477344 | Improved Methodology for the Synthesis of a Cathepsin B Cleavable Dipeptide Linker, Widely Used in Antibody-Drug Conjugate Research |
| Q92750453 | Increasing the Potential of the Auristatin Cancer-Drug Family by Shifting the Conformational Equilibrium |
| Q36944649 | Influence of the linker on the biodistribution and catabolism of actinium-225 self-immolative tumor-targeted isotope generators |
| Q35765517 | Inhibition of cancer cell proliferation and breast tumor targeting of pHLIP-monomethyl auristatin E conjugates. |
| Q38537257 | Internalization, Trafficking, Intracellular Processing and Actions of Antibody-Drug Conjugates |
| Q41282870 | Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates |
| Q92192885 | Investigation of Antibody-Drug Conjugates by Mass Spectrometry |
| Q37818256 | Investigational antibody-drug conjugates for hematological malignancies |
| Q21256651 | Killing cancer cells by targeted drug-carrying phage nanomedicines |
| Q26752763 | Linkers Having a Crucial Role in Antibody-Drug Conjugates |
| Q40315198 | Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates |
| Q92495346 | Marine-Derived Anticancer Agents: Clinical Benefits, Innovative Mechanisms, and New Targets |
| Q28075572 | Marine-Derived Pharmaceuticals - Challenges and Opportunities |
| Q37566220 | Marine-sourced anti-cancer and cancer pain control agents in clinical and late preclinical development |
| Q38960075 | Mechanistic pharmacokinetic/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates |
| Q33591348 | Metal Nanoshell - Capsule for Light-Driven Release of Small Molecule |
| Q37593707 | Methods for site-specific drug conjugation to antibodies |
| Q34655256 | Microtubule inhibitor-based antibody-drug conjugates for cancer therapy |
| Q36739759 | Monoclonal antibody-based therapeutics for leukemia |
| Q47148105 | Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer |
| Q26766540 | New developments for antibody-drug conjugate-based therapeutic approaches |
| Q45435082 | New insight on the structural features of the cytotoxic auristatins MMAE and MMAF revealed by combined NMR spectroscopy and quantum chemical modelling |
| Q42871498 | Next generation maleimides enable the controlled assembly of antibody-drug conjugates via native disulfide bond bridging |
| Q39112394 | On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach |
| Q38024991 | Optimising the delivery of tubulin targeting agents through antibody conjugation |
| Q38726286 | Orthogonal Cysteine Protection Enables Homogeneous Multi-Drug Antibody-Drug Conjugates |
| Q92290774 | Pharmacokinetic and Metabolism Studies of Monomethyl Auristatin F via Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometry |
| Q34257256 | Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors |
| Q64448611 | Phase I Trials of Anti-ENPP3 Antibody-Drug Conjugates in Advanced Refractory Renal Cell Carcinomas |
| Q57347954 | Poly(methacrylic acid) complexation of amphotericin B to treat neglected diseases |
| Q90616314 | Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability |
| Q36982570 | Prodrug strategies in anticancer chemotherapy |
| Q26782485 | Progress and Challenges in Developing Aptamer-Functionalized Targeted Drug Delivery Systems |
| Q38798525 | Prospects and progress of antibody-drug conjugates in solid tumor therapies |
| Q34838057 | Protein conjugation with genetically encoded unnatural amino acids |
| Q92594627 | Proteolysis and Oxidation of Therapeutic Proteins After Intradermal or Subcutaneous Administration |
| Q44302601 | Quantification of nanowire penetration into living cells |
| Q100671892 | Rational Design of Azastatin as a Potential ADC Payload with Reduced Bystander Killing |
| Q38863927 | Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index |
| Q27303016 | Site-Dependent Degradation of a Non-Cleavable Auristatin-Based Linker-Payload in Rodent Plasma and Its Effect on ADC Efficacy |
| Q39959127 | Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. |
| Q28546010 | Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency |
| Q26780335 | Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics |
| Q28553497 | Structural Basis of Microtubule Destabilization by Potent Auristatin Anti-Mitotics |
| Q92165417 | Synthesis and Biological Evaluation of RGD and isoDGR-Monomethyl Auristatin Conjugates Targeting Integrin αV β3 |
| Q90335566 | Synthesis and Evaluation of Linear and Macrocyclic Dolastatin 10 Analogues Containing Pyrrolidine Ring Modifications |
| Q24624489 | Synthesis of site-specific antibody-drug conjugates using unnatural amino acids |
| Q52676610 | Targeted Delivery of Auristatin-Modified Toxins to Pancreatic Cancer Using Aptamers. |
| Q26746934 | Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and Future |
| Q39310345 | Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates |
| Q65000833 | Targeting the human MUC1-C oncoprotein with an antibody-drug conjugate. |
| Q36773469 | Technology insight: cytotoxic drug immunoconjugates for cancer therapy |
| Q64093909 | The Analysis of Key Factors Related to ADCs Structural Design |
| Q38092648 | The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics |
| Q35788245 | The development of potential antibody-based therapies for myeloma |
| Q48099690 | Therapeutic Efficacy of a Family of pHLIP-MMAF Conjugates in Cancer Cells and Mouse Models |
| Q90198363 | Therapeutic Targeting of Golgi Phosphoprotein 2 (GOLPH2) with Armed Antibodies: A Preclinical Study of Anti-GOLPH2 Antibody Drug Conjugates in Lung and Colorectal Cancer Models of Patient Derived Xenografts (PDX) |
| Q43525091 | Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies. |
| Q39904011 | Toxicity-reducing potential of extracorporeal affinity adsorption treatment in combination with the auristatin-conjugated monoclonal antibody BR96 in a syngeneic rat tumor model |
| Q38162127 | Trends in cancer-targeted antibody-drug conjugates. |
| Q38648690 | Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy. |
| Q35765100 | Tumor-targeting drug delivery of new-generation taxoids |
| Q52582168 | Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer. |
| Q37959880 | What happened to anti-CD33 therapy for acute myeloid leukemia? |
Search more.